CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Zenabis outperforms revised cannabis design capacity by 41% in August
Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...
Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.
Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...
FDA approves Kadmon Holdings’ generic Wilson’s disease drug
The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...
MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors
Online continuing professional development provider, MDBriefCase Group (MDBC), is collaborating with Dr. David Strain, senior clinical lecturer at the University of Exeter and Dr. Mohamed Farghaly, associate professor...
Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments
OrthoSpin, a portfolio of company of The Trendlines Group (OTCQX:TRNLY; SGX:42T) received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The use of external...
Titan Pharma gets second year of NIDA funding for nalmefene implant development
The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...
WB starts Axsome Therapeutics at OP; fair value estimate $48
William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...
Stereotaxis names Kimberly Peery as CFO
Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis area. He will...
WB starts Minerva Neurosciences at OP; fair value estimate $26
William Blair launched coverage of Minerva Neurosciences (NASDAQ:NERV) with an “outperform” rating and fair value estimate of $26. The stock closed at $8.11 on Sept. 17. Minerva is developing therapies for mood...
Just a few of the companies we’ve highlighted along the way
